Amydis_Logo_Horiz_RGB@2x.png
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies
April 26, 2021 07:00 ET | Amydis, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy
January 11, 2021 07:00 ET | Amydis, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye
August 11, 2020 07:00 ET | Amydis, Inc.
SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina,...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy
September 23, 2019 07:00 ET | Amydis, Inc.
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases,...
Amydis_Logo_Horiz_RGB@2x.png
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
October 24, 2018 07:00 ET | Amydis, Inc.
LOS ANGELES, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by...
Amydis_Logo_Horiz_RGB@2x.png
UPDATE - Amydis Awarded Prion Disease Grant from NIH
September 26, 2018 14:05 ET | Amydis, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative technology to detect amyloid-related diseases,...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Awarded Prion Disease Grant from NIH
September 26, 2018 07:00 ET | Amydis, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative technology to detect amyloid-related diseases,...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Receives Parkinson’s Disease Grant from Michael J. Fox Foundation
July 10, 2018 07:00 ET | Amydis, Inc.
SAN DIEGO, July 10, 2018 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related...
Amydis_Logo_Horiz_RGB@2x.png
NIH Awards Cerebral Amyloid Angiopathy Grant to Amydis Diagnostics
October 09, 2017 09:14 ET | Amydis Diagnostics, Inc.
SAN DIEGO, Oct. 09, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Diagnostics Named to San Diego Venture Group’s (SDVG) 2017 Cool Companies List
May 30, 2017 09:00 ET | Amydis Diagnostics, Inc.
SAN DIEGO, May 30, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to...